Abstract
Purpose Non-infectious uveitis (“uveitis”) is an important cause of visual loss amongst children. Although TNFa inhibitors (anti-TNFa) are increasingly used to treat pediatric uveitis, the outcomes of treatment with these agents have been poorly described. We are studying the largest, and only multicenter, group of patients with pediatric uveitis in order to more precisely estimate the outcomes of treatment with anti-TNFa and to evaluate which factors increase the likelihood of achieving uveitis quiescence after treatment. The final cohort will include subjects from the five-center Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, The Children’s Hospital of Philadelphia (CHOP), and Hershey Medical Center. Here we report preliminary results from subjects at CHOP.
Highlights
Non-infectious uveitis (“uveitis”) is an important cause of visual loss amongst children
We are studying the largest, and only multicenter, group of patients with pediatric uveitis in order to more precisely estimate the outcomes of treatment with anti-TNFa and to evaluate which factors increase the likelihood of achieving uveitis quiescence after treatment
Active uveitis was defined according to the SUN Working Group (2005)
Summary
Non-infectious uveitis (“uveitis”) is an important cause of visual loss amongst children. TNFa inhibitors (anti-TNFa) are increasingly used to treat pediatric uveitis, the outcomes of treatment with these agents have been poorly described. We are studying the largest, and only multicenter, group of patients with pediatric uveitis in order to more precisely estimate the outcomes of treatment with anti-TNFa and to evaluate which factors increase the likelihood of achieving uveitis quiescence after treatment. The final cohort will include subjects from the five-center Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, The Children’s Hospital of Philadelphia (CHOP), and Hershey Medical Center. We report preliminary results from subjects at CHOP
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
